🍽️ sulfacetamide sodic hydrate (antibiotic)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Treatment of Bacterial Infections: Sulfacetamide sodium is primarily used to treat bacterial infections of the skin, such as acne vulgaris, rosacea, and seborrheic dermatitis. It is also used in the treatment of bacterial conjunctivitis (pink eye) and other eye infections caused by susceptible organisms.

  2. Mechanism of Action: Sulfacetamide sodium works by inhibiting the growth and reproduction of bacteria. It is a sulfonamide antibiotic that interferes with the synthesis of dihydrofolic acid, a precursor to folate, which is essential for bacterial growth. By inhibiting the enzyme dihydropteroate synthase, sulfacetamide sodium disrupts the production of folate, ultimately leading to bacterial cell death.

  3. Topical and Ophthalmic Formulations: Sulfacetamide sodium is available in various formulations for topical application to the skin and as eye drops for ocular use. Topical formulations may be in the form of creams, lotions, gels, or cleansers, while ophthalmic formulations are typically in the form of eye drops.

  4. Broad Spectrum of Activity: Sulfacetamide sodium has a broad spectrum of activity against both gram-positive and gram-negative bacteria, including common pathogens such as Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, and Haemophilus influenzae, among others.

  5. Anti-inflammatory Properties: In addition to its antibacterial effects, sulfacetamide sodium may have anti-inflammatory properties that contribute to its efficacy in the treatment of inflammatory skin conditions such as acne and rosacea. It can help reduce redness, swelling, and inflammation associated with these conditions.

  6. Adverse Effects: Common side effects of sulfacetamide sodium may include local irritation, burning, stinging, or itching at the site of application. Rare but serious adverse effects may include allergic reactions, severe skin reactions (e.g., Stevens-Johnson syndrome), or eye irritation and sensitivity with ocular use. It is essential to discontinue use and seek medical attention if any adverse reactions occur.

  7. Pregnancy and Lactation: The safety of sulfacetamide sodium use during pregnancy and lactation has not been well established. While topical use may pose minimal risk, systemic absorption and potential effects on the fetus or breastfeeding infant should be considered. The use of sulfacetamide sodium during pregnancy and lactation should be based on a careful assessment of the benefits and risks and under the guidance of a healthcare professional.

  8. Bacterial Resistance: As with other antibiotics, the overuse or misuse of sulfacetamide sodium can contribute to the development of bacterial resistance. It is essential to use sulfacetamide sodium judiciously and according to specific treatment guidelines to minimize the risk of resistance and ensure optimal efficacy.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of sulfacetamide sodic hydrate (antibiotic) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by sulfacetamide sodic hydrate (antibiotic)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Ruminococcus genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Bacteroides caccae species Decreases 📓 Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Blautia obeum species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
Coprococcus comes species Decreases 📓 Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of sulfacetamide sodic hydrate (antibiotic) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.1 -0.1
ADHD 0.7 0.1 6
Allergic Rhinitis (Hay Fever) 0.1 0.3 -2
Allergies 0.4 0.6 -0.5
Allergy to milk products 0.4 0.1 3
Alopecia (Hair Loss) 0.1 0.1
Alzheimer's disease 0.6 0.7 -0.17
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.8 0.5 0.6
Ankylosing spondylitis 0.3 0.5 -0.67
Anorexia Nervosa 0.6 -0.6
Antiphospholipid syndrome (APS) 0.1 0.1
Asthma 0.1 0.3 -2
Atherosclerosis 0.3 0.1 2
Atrial fibrillation 0.7 0.2 2.5
Autism 0.7 1.5 -1.14
benign prostatic hyperplasia 0 0
Bipolar Disorder 0.4 0.3 0.33
Brain Trauma 0.1 0.1 0
Cancer (General) 0.4 -0.4
Carcinoma 0.5 0.5 0
Celiac Disease 0.2 0.9 -3.5
Cerebral Palsy 0.2 0.4 -1
Chronic Fatigue Syndrome 1.3 0.5 1.6
Chronic Kidney Disease 0.1 0.3 -2
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 0.3 -0.3
Chronic Urticaria (Hives) 0.1 0.1 0
Coagulation / Micro clot triggering bacteria 0.1 0.3 -2
Colorectal Cancer 0.6 0.1 5
Constipation 0.3 0.1 2
Coronary artery disease 0.2 0.1 1
COVID-19 1.2 2 -0.67
Crohn's Disease 0.7 1.2 -0.71
cystic fibrosis 0.1 0.2 -1
deep vein thrombosis 0.1 0.2 -1
Depression 1.2 1.1 0.09
Dermatomyositis 0.1 -0.1
Eczema 0 0.1 0
Endometriosis 0.4 0.4 0
Epilepsy 0.3 0.4 -0.33
Fibromyalgia 0.1 0.3 -2
Functional constipation / chronic idiopathic constipation 1.1 0.4 1.75
gallstone disease (gsd) 0.4 0.1 3
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.1 -0.1
Generalized anxiety disorder 0.2 0.4 -1
Gout 0.1 -0.1
Graves' disease 0.2 0.1 1
Halitosis 0.1 0.1
Hashimoto's thyroiditis 0.3 0.2 0.5
Histamine Issues 0.6 0.1 5
hypercholesterolemia (High Cholesterol) 0.1 -0.1
hyperglycemia 0 0.4 0
Hyperlipidemia (High Blood Fats) 0.2 0.2
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 0.5 0.5 0
Hypothyroidism 0.2 -0.2
Hypoxia 0.1 0.1
IgA nephropathy (IgAN) 0.7 -0.7
Inflammatory Bowel Disease 0.3 1.6 -4.33
Insomnia 0.1 0.3 -2
Intelligence 0.1 0.1
Intracranial aneurysms 0.4 0.4
Irritable Bowel Syndrome 0.8 0.6 0.33
Liver Cirrhosis 0.6 0.5 0.2
Long COVID 0.8 1.9 -1.37
Low bone mineral density 0.3 -0.3
Lung Cancer 0.2 0.4 -1
Mast Cell Issues / mastitis 0 0.4 0
ME/CFS with IBS 0.4 -0.4
ME/CFS without IBS 0.1 0.2 -1
Menopause 0.3 0.3
Metabolic Syndrome 0.9 1 -0.11
Mood Disorders 1.6 1.1 0.45
multiple chemical sensitivity [MCS] 0.1 0.1 0
Multiple Sclerosis 0.8 0.7 0.14
Multiple system atrophy (MSA) 0.2 0.4 -1
neuropathic pain 0.4 -0.4
Neuropathy (all types) 0.1 0 0
neuropsychiatric disorders (PANDAS, PANS) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.1 1.2 -11
NonCeliac Gluten Sensitivity 0.1 -0.1
Obesity 0.8 0.7 0.14
obsessive-compulsive disorder 1.2 0.4 2
Osteoarthritis 0.1 0.2 -1
Osteoporosis 0.4 0.3 0.33
Parkinson's Disease 0.4 0.6 -0.5
Polycystic ovary syndrome 0.4 0.6 -0.5
Postural orthostatic tachycardia syndrome 0.2 -0.2
Premenstrual dysphoric disorder 0.2 0.2
Psoriasis 0.6 0.3 1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.8 0.2 3
Rosacea 0.3 0.3
Schizophrenia 1 0.5 1
scoliosis 0.1 0.6 -5
Sjögren syndrome 0.1 0.2 -1
Sleep Apnea 0.5 0.2 1.5
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.2 -1
Stress / posttraumatic stress disorder 0.3 0.3 0
Systemic Lupus Erythematosus 0.3 0.6 -1
Tic Disorder 0.2 0.1 1
Tourette syndrome 0.1 0.1 0
Type 1 Diabetes 0.7 0.2 2.5
Type 2 Diabetes 0.9 0.9 0
Ulcerative colitis 0.4 0.6 -0.5
Unhealthy Ageing 0.1 0.2 -1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]